Skip to main content

Novel Rx

    The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress,…
    In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require…
    RT @MeralElRamahiMD: OP0140 at #EULAR2021:
    ➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASD
    2 years 10 months ago
    OP0140 at #EULAR2021: ➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz) ➡️1 in 10 received at least 3 bDMARDs *⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis @Rheumnow https://t.co/syq0szVWKe
    RT @doctorRBC: Baseline Vitamin D 😎☀️correlated with biologic response in RA pts.
    ⭐️EULAR good response: 19.6
    2 years 10 months ago
    Baseline Vitamin D 😎☀️correlated with biologic response in RA pts. ⭐️EULAR good response: 19.6% Vit D >20 vs 4.2%⬇️Vit D ⭐️Remission: 14.4% ⬆️Vit D vs 3.2% ⬇️Vit D Abs#POS0100 #EULAR2021 @RheumNow
    RT @Yuz6Yusof: No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #
    2 years 10 months ago
    No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #psoriaticarthritis with severe #psoriasis. Thank you for participating in the polls #EULAR2021 @RheumNow https://t.co/b8wzaRVTqw
    RT @drdavidliew: Rituximab in PMR. Intriguing

    proof of concept (SB?) RCT
    (1:1, total n=47 (recent dx 38/relapsing 9))
    1
    2 years 10 months ago
    Rituximab in PMR. Intriguing proof of concept (SB?) RCT (1:1, total n=47 (recent dx 38/relapsing 9)) 17w rapid PNL taper ritux 1g x1 21w: steroid-free remission: 48% v 21% PNL ≤5mg/d: 100% v 54% effect mainly from recent dx pts We do need options! POS0343 #EULAR2021 @RheumNow https://t.co/g6xJekY92O
    RT @uptoTate: HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to r
    2 years 10 months ago
    HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to remain on csDMARDs.) This distinction may be explained by synthetic DMARDs on activity differences between the RA & PsA. Abstract #POS0633 #EULAR2021 https://t.co/VkkF28jm2f https://t.co/IkfGdZYNY3
    RT @uptoTate: Poster #POS0633 detailed HUR-BIO PsA pts started bDMARDs w/in 18 months of dx vs, on ave, 3x longer to sta
    2 years 10 months ago
    Poster #POS0633 detailed HUR-BIO PsA pts started bDMARDs w/in 18 months of dx vs, on ave, 3x longer to start bDMARDs in RA pts in real life data. What do you drugs do you start in your PsA pts after dx? Feel free to detail me below! #EULAR2021 @RheumNow